Drug intelligence / Profile preview

QHL-718

Development stage: Preclinical
Lead developer: Affinity Biopharmaceutical
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

QHL-718 is a small molecule drug conjugate (SMDC) developed by Affinity Biopharmaceutical for the treatment of solid tumors. It is part of the company's 'Precision Guided Target Therapy' pipeline and is designed to simultaneously target the Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF) pathways. These pathways are key mediators of tumor angiogenesis and proliferation. By utilizing the SMDC platform, QHL-718 aims to deliver a cytotoxic payload directly to the tumor site, potentially increasing therapeutic efficacy while reducing systemic side effects. As of late 2024, the drug is in the preclinical stage of development.

Targets

VEGFA (Vascular endothelial growth factor A)FGF (Fibroblast growth factor 6)

Beyond the preview

Go deeper on QHL-718.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QHL-718.

Explore the full profile